Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXGN NASDAQ:EMBC NYSE:NVRO NASDAQ:TNDM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXGNAxoGen$16.27+0.8%$12.76$9.22▼$21.00$742.19M1820,093 shs1.16 million shsEMBCEmbecta$14.54-0.4%$11.22$9.20▼$21.48$850.97M1.08601,256 shs272,951 shsNVRONevro$5.85+0.1%$5.85$3.17▼$10.34$224.32M0.81818,428 shs753,602 shsTNDMTandem Diabetes Care$11.75-4.1%$15.10$9.98▼$47.60$792.73M1.461.73 million shs1.51 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXGNAxoGen-0.43%+3.73%+24.25%+48.07%+26.99%EMBCEmbecta+2.67%+5.04%+28.77%+39.62%-0.14%NVRONevro0.00%0.00%0.00%0.00%+0.45%TNDMTandem Diabetes Care+0.08%+14.70%-27.26%-42.43%-73.12%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAXGNAxoGen2.4729 of 5 stars3.52.00.00.02.61.70.6EMBCEmbecta4.7653 of 5 stars3.43.03.30.04.11.73.8NVRONevroN/AN/AN/AN/AN/AN/AN/AN/ATNDMTandem Diabetes Care4.6316 of 5 stars4.13.00.04.93.11.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXGNAxoGen 3.00Buy$26.0059.85% UpsideEMBCEmbecta 2.75Moderate Buy$19.0030.72% UpsideNVRONevro 2.00Hold$5.36-8.29% DownsideTNDMTandem Diabetes Care 2.27Hold$22.4791.29% UpsideCurrent Analyst Ratings BreakdownLatest NVRO, EMBC, TNDM, and AXGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/26/2025EMBCEmbectaZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy8/21/2025TNDMTandem Diabetes CareCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$10.35 ➝ $11.008/11/2025TNDMTandem Diabetes CareLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$75.00 ➝ $12.008/8/2025TNDMTandem Diabetes CareBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$53.00 ➝ $51.008/7/2025TNDMTandem Diabetes CareCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$59.00 ➝ $24.008/7/2025TNDMTandem Diabetes CarePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$30.00 ➝ $14.008/7/2025TNDMTandem Diabetes CareUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$20.00 ➝ $17.008/7/2025TNDMTandem Diabetes CareWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$20.00 ➝ $13.008/7/2025TNDMTandem Diabetes CareRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$45.00 ➝ $25.007/16/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$13.00 ➝ $12.007/9/2025TNDMTandem Diabetes CareCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Sell$24.00 ➝ $14.00(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXGNAxoGen$203.27M3.68N/AN/A$2.44 per share6.67EMBCEmbecta$1.12B0.76$3.41 per share4.26($11.45) per share-1.27NVRONevro$408.52M0.55N/AN/A$8.10 per share0.72TNDMTandem Diabetes Care$940.20M0.84N/AN/A$1.97 per share5.96Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXGNAxoGen-$9.96M-$0.10N/AN/AN/A-2.29%-4.43%-2.34%11/6/2025 (Estimated)EMBCEmbecta$78.30M$1.4310.174.730.797.58%-23.40%14.46%N/ANVRONevro-$92.21M-$3.05N/AN/AN/A-16.54%-23.52%-10.83%N/ATNDMTandem Diabetes Care-$96.03M-$3.09N/AN/AN/A-20.51%-65.40%-13.87%11/5/2025 (Estimated)Latest NVRO, EMBC, TNDM, and AXGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q3 2025EMBCEmbecta$0.7720$1.12+$0.3480$0.78$278.15 million$295.50 million8/6/2025Q2 2025TNDMTandem Diabetes Care-$0.40-$0.48-$0.08-$0.78$238.39 million$240.68 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAXGNAxoGenN/AN/AN/AN/AN/AEMBCEmbecta$0.604.13%N/A41.96%N/ANVRONevroN/AN/AN/AN/AN/ATNDMTandem Diabetes CareN/AN/AN/AN/AN/ALatest NVRO, EMBC, TNDM, and AXGN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date8/6/2025EMBCEmbectaquarterly$0.155.79%8/29/20258/29/20259/15/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXGNAxoGen0.594.142.67EMBCEmbectaN/A2.471.78NVRONevro0.675.023.76TNDMTandem Diabetes Care2.322.441.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXGNAxoGen80.29%EMBCEmbecta93.83%NVRONevro95.52%TNDMTandem Diabetes CareN/AInsider OwnershipCompanyInsider OwnershipAXGNAxoGen2.78%EMBCEmbecta0.42%NVRONevro3.20%TNDMTandem Diabetes Care1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXGNAxoGen45046.01 million44.73 millionOptionableEMBCEmbecta2,10058.49 million58.24 millionOptionableNVRONevro1,09038.37 million36.27 millionOptionableTNDMTandem Diabetes Care2,65067.57 million66.29 millionOptionableNVRO, EMBC, TNDM, and AXGN HeadlinesRecent News About These CompaniesTandem Diabetes Care, Inc. $TNDM Shares Acquired by HighTower Advisors LLCAugust 28 at 3:37 AM | marketbeat.comNuveen LLC Invests $5.91 Million in Tandem Diabetes Care, Inc. $TNDMAugust 28 at 3:36 AM | marketbeat.comRussell Investments Group Ltd. Has $2.67 Million Stake in Tandem Diabetes Care, Inc. $TNDMAugust 27 at 3:38 AM | marketbeat.comCharles Schwab Investment Management Inc. Sells 32,171 Shares of Tandem Diabetes Care, Inc. $TNDMAugust 26 at 3:21 AM | marketbeat.comTandem Diabetes Care (NASDAQ:TNDM) Stock Price Up 7.4% Following Analyst UpgradeAugust 24, 2025 | americanbankingnews.comTandem Diabetes Care Inc News (TNDM) - Investing.comAugust 23, 2025 | investing.comTandem Diabetes Care, Inc. $TNDM Shares Purchased by Aberdeen Group plcAugust 23, 2025 | marketbeat.comVanguard Group Inc. Reduces Holdings in Tandem Diabetes Care, Inc. $TNDMAugust 23, 2025 | marketbeat.comTandem Diabetes Care (TNDM) Gets a Buy from RBC CapitalAugust 22, 2025 | theglobeandmail.comVersor Investments LP Buys Shares of 30,500 Tandem Diabetes Care, Inc. $TNDMAugust 22, 2025 | marketbeat.comAlgert Global LLC Purchases 119,784 Shares of Tandem Diabetes Care, Inc. $TNDMAugust 22, 2025 | marketbeat.comCitigroup Boosts Tandem Diabetes Care (NASDAQ:TNDM) Price Target to $11.00August 22, 2025 | americanbankingnews.comPublic Sector Pension Investment Board Raises Stock Position in Tandem Diabetes Care, Inc. $TNDMAugust 19, 2025 | marketbeat.comSector Gamma AS Acquires New Shares in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)August 17, 2025 | marketbeat.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Given Consensus Rating of "Hold" by BrokeragesAugust 15, 2025 | marketbeat.comTandem Diabetes Care, Inc. (TNDM) Investors Who Lost Money - Contact Law Offices of Howard G. Smith About Securities Fraud InvestigationAugust 14, 2025 | tmcnet.comSecurities Fraud Investigation Into Tandem Diabetes Care, Inc. ...August 14, 2025 | gurufocus.comSecurities Fraud Investigation Into Tandem Diabetes Care, Inc. (TNDM) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law FirmAugust 14, 2025 | businesswire.comTandem Diabetes Care, Inc. (TNDM) Investors Who Lost Money -- Contact Law Offices of Howard G. ...August 14, 2025 | gurufocus.comTandem Diabetes Care, Inc. (TNDM) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud InvestigationAugust 14, 2025 | businesswire.comSecurities Fraud Investigation Into Tandem Diabetes Care, Inc. (TNDM) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. CruzAugust 13, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNVRO, EMBC, TNDM, and AXGN Company DescriptionsAxoGen NASDAQ:AXGN$16.26 +0.13 (+0.77%) As of 03:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.Embecta NASDAQ:EMBC$14.54 -0.06 (-0.38%) As of 03:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.Nevro NYSE:NVRONevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.Tandem Diabetes Care NASDAQ:TNDM$11.74 -0.51 (-4.12%) As of 03:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike at a Crossroads: AI Halo vs. Risks NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It NIO Just Got Its Second Upgrade of the Month, and It’s Big As Bitcoin Falls and Ethereum Rallies, Coinbase Stock Comes Back Williams-Sonoma Q2 Results Prove Its Buy-and-Hold Quality Okta: Market Comes to a Boil, Explosive Upside Is Possible MongoDB Roars Back to Life: It’s Not Too Late to Buy More Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access